Umberto Bosio Center for Digestive Diseases, The Children Hospital, AOU SS Antonio e Biagio e Cesare Arrigo, Spalto Marengo, 46, 15121, Alessandria, Italy.
M L Novi studies specific cells in colon cancer, particularly a type called CD133+ cells. These cells are often linked to more severe forms of cancer and a higher likelihood of spreading (metastasis) to other organs like the liver. By examining the characteristics of these cells, Dr. Novi aims to understand why they are more effective at growing and spreading compared to other cancer cells. This research is crucial for developing targeted therapies that can combat the most dangerous aspects of colon cancer.
Key findings
CD133+ cells were found in 100% of colon tumors and 75% of liver metastases, indicating their prevalence in aggressive cancer forms.
The study revealed that CD133+ cells produced larger and more numerous colonies than other cancer cells, suggesting they are key drivers of cancer growth.
A significantly higher percentage of CD133+ cells was detected in liver metastases compared to primary colon tumors, pointing to their role in cancer spread.
Frequently asked questions
Does Dr. Novi study colon cancer?
Yes, Dr. Novi specializes in research related to colon cancer, focusing particularly on aggressive cancer cell types.
What are CD133+ cells?
CD133+ cells are a specific population of cancer cells that are associated with more aggressive forms of colon cancer and are believed to drive cancer growth.
How is this research relevant to patients?
This research helps patients by identifying the most dangerous cancer cells, which can lead to better-targeted therapies for colon cancer.
Publications in plain English
Delayed diagnosis in Hirschsprung disease.
2024
Pediatric surgery international
Pini Prato A, Erculiani M, Novi ML, Caraccia M, Grandi A +4 more
Plain English This study focused on individuals with Hirschsprung disease who were diagnosed later than 12 months of age. Researchers found that out of 346 patients, 45 were diagnosed late, with the average age of diagnosis being 41 months. While most had mild symptoms that led to missed diagnoses, the overall health outcomes for these late-diagnosed patients were similar to those diagnosed on time.
Who this helps: This helps patients and their families by highlighting the need for better diagnosis practices.
A unicentric cross-sectional observational study on chronic intestinal inflammation in total colonic aganglionosis: beware of an underestimated condition.
2023
Orphanet journal of rare diseases
Erculiani M, Poluzzi F, Mottadelli G, Felici E, Ml N +13 more
Plain English This study looked at chronic intestinal inflammation in patients with Total Colonic Aganglionosis (TCSA), a condition related to Hirschsprung disease. They found that around 50% of the patients tested positive for signs of inflammation, and 36.8% had Crohn-like lesions years after their surgery. This is significant because it highlights that patients with TCSA have a much higher risk—ten times greater—of developing chronic intestinal issues than previously thought, suggesting that regular screenings could be important for their care.
Who this helps: This helps patients with TCSA and their doctors by emphasizing the need for better monitoring and prevention of intestinal inflammation.
Isolation and characterization of CD133+ cell population within human primary and metastatic colon cancer.
2009
European review for medical and pharmacological sciences
Puglisi MA, Sgambato A, Saulnier N, Rafanelli F, Barba M +13 more
Plain English This study looked at specific cancer cells called CD133+ cells in colon cancer and its spread to the liver. Researchers found that these CD133+ cells existed in both colon tumors and liver metastases, with a higher percentage in liver metastases. The CD133+ cells were also shown to produce larger and more numerous colonies compared to other cancer cells, indicating they may be key drivers of cancer growth and spread.
Who this helps: This research benefits patients with colon cancer by providing insight into the most aggressive cancer cells.